Lipogems, an Atlanta, GA-based clinical stage medical technology company, raised €12.5M in Growth funding.
The round was led by ABC Medtech and LIFTT.
The company intends to use the funds to support the recent FDA approved IDE Studies for a separate and specific indication in Knee Osteoarthritis (OA).
Lipogems is a clinical stage- global medical technology company that utilizes autologous adipose tissue for therapeutic use in orthopaedics and other specialties. Its minimally invasive procedure is performed one time in a sterile setting (outpatient or operating room) in about 40 minutes and has shown in independent, investigator-initiated studies to improve the pain, function and quality of life of patients with this disabling disease. Its products are used in a diverse range of areas, including orthopaedics, general surgery, plastic and reconstructive surgery.
Lipogems is available in 29 countries.
FinSMEs
25/12/2022